Insights

Gathering insights about Telo…

Similar companies to Telo

Telo Tech Stack

Telo uses 8 technology products and services including AppNexus, Amazon Web Services, AngularJS, and more. Explore Telo's tech stack below.

AppNexus
Advertising
Amazon Web Services
Cloud Hosting
AngularJS
Javascript Frameworks
jQuery
Javascript Libraries
Bootstrap
UI Frameworks
mod_wsgi
Web Server Extensions
Apache
Web Servers
Google Plus
Widgets

Media & News

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS Newswire / January 5, 2026 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of diseases, today announced results from a completed efficacy study evaluating Telomir-1 (Zn-Telomir) in zebrafish tumor xenograft animal models of triple-negative breast cancer (TNBC).
Jan 05, 2026 | www.accessnewswire.com
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO - Get Free Report) was down 8.9% on Monday. The stock traded as low as $1.32 and last traded at $1.33. Approximately 579,108 shares traded hands during mid-day trading, an increase of 171% from the average daily volume of 213,869 shares. The stock had previously closed at $1.46. Wall Street
Dec 30, 2025 | www.defenseworld.net
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today announced favorable results from a comprehensive series of IND-enabling Good Laboratory Practice (GLP) toxicology and safety pharmacology studies for its lead therapeutic candidate, Telomir-1 (Zn-Telomir).
Dec 18, 2025 | www.accessnewswire.com
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November 25, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today reported new preclinical findings demonstrating that its lead therapeutic candidate, Telomir-1, reduced PSA (prostate-specific antigen) levels in androgen-responsive human prostate cancer cells (LNCaP).
Nov 25, 2025 | www.accessnewswire.com
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL / ACCESS Newswire / November 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapies targeting the epigenetic and metabolic roots of cancer, aging, and age-related disease, today announced new in vitro findings showing that its investigational compound Telomir-1 kills aggressive human leukemia (HL60) cells.
Nov 21, 2025 | www.accessnewswire.com
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating activity - key to its broader epigenetic mechanism of action. MIAMI, FL / ACCESS Newswire / November 12, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies targeting the epigenetic roots of cancer, aging, and age-related disease, today announced new preclinical findings showing that its lead investigational compound Telomir-1 produced a strong, dose-dependent reduction of intracellular iron in human keratinocyte (HaCaT) cells - outperforming the FDA-approved gold-standard iron chelator, Deferoxamine (DFO).
Nov 12, 2025 | www.accessnewswire.com
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ACCESS Newswire / October 23, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical biotechnology company developing therapies that target the epigenetic roots of cancer, aging, and age-related disease, today reported new preclinical data from an in vivo study in mice bearing human aggressive prostate cancer tumors evaluating DNA-methylation changes in two key defense genes - CASP8 and GSTP1 - following treatment with oral Telomir-1, Rapamycin, chemotherapy, and combination regimens.
Oct 23, 2025 | www.accessnewswire.com

Telo's Email Address Formats

Telo uses at least 1 format(s):

Telo Email Formats	Example	Percentage
First.Last@telo.com	John.Doe@telo.com	50%
First.Last@telo.com	John.Doe@telo.com	50%

Frequently Asked Questions

Where is Telo's headquarters located?

Telo's main headquarters is located at 53 Calle Las Palmeras, Suite 702. The company has employees across 2 continents, including North AmericaAfrica.

What is Telo's stock symbol?

Telo is a publicly traded company; the company's stock symbol is TELO.

What is Telo's official website and social media links?

Telo's official website is telo.com and has social profiles on LinkedIn.

What is Telo's NAICS code?

Telo's NAICS code is 517 - Telecommunications.

How many employees does Telo have currently?

As of December 2025, Telo has approximately 12 employees across 2 continents, including North AmericaAfrica. Key team members include Financial Controller: S. W.Sales And Support Specialist: M. C.. Explore Telo's employee directory with LeadIQ.

What industry does Telo belong to?

Telo operates in the Telecommunications industry.

What technology does Telo use?

Telo's tech stack includes AppNexusAmazon Web ServicesAngularJSjQueryBootstrapmod_wsgiApacheGoogle Plus.

What is Telo's email format?

Telo's email format typically follows the pattern of First.Last@telo.com. Find more Telo email formats with LeadIQ.

When was Telo founded?

Telo was founded in 2015.

Telo

Q: What is Telo's official website and social media links?

Telo's official website is telo.com. Telo has social profiles on LinkedIn.

Q: How many employees does Telo have currently?

Telo has approximately 12 employees.

Q: What technology does Telo use?

Telo's tech stack includes AppNexus, mod_wsgi, Bootstrap, Google Plus, Apache.

TelecommunicationsTexas, United States11-50 Employees

Telo pioneered the first developer friendly telephony data API in 2011 with the launch of OpenCNAM. Since then, Telo has expanded its developer focused product line to include EveryoneAPI, a highly advanced reverse phone append API, and released subsequent versions of OpenCNAM that have extended Caller ID coverage to over 229 countries. Today, Telo is committed to leading data services innovation by providing APIs that supply systems worldwide with information that is rooted in exhaustive research and avant-garde intelligence.

Company Overview

Headquarters: 53 Calle Las Palmeras, Suite 702
Website: telo.com
Stock Symbol: TELO
NAICS Code: 517 - Telecommunications
Founded: 2015
Employees: 11-50

Media & News

Funding & Financials

$1M$10M
Telo's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$1M$10M
Telo's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Telo

8x8

Nextiva

Grasshopper

RingCentral

Net2Phone

Dialpad

magicJack

Vocalocity

Telo Tech Stack

Media & News

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo

Telo's Email Address Formats

Frequently Asked Questions

Where is Telo's headquarters located?

What is Telo's stock symbol?

What is Telo's official website and social media links?

What is Telo's NAICS code?

How many employees does Telo have currently?

What industry does Telo belong to?

What technology does Telo use?

What is Telo's email format?

When was Telo founded?

Telo

Company Overview

Media & News

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?